News
-
-
PRESS RELEASE
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Bausch Health appoints Michael Goettler and Sandra Leung to its Board of Directors, expanding the Board to twelve members. The new appointments bring extensive pharmaceutical industry expertise and leadership experience -
-
PRESS RELEASE
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
Bausch Health, Canada introduces CABTREO gel for acne treatment to public drug plans in Ontario, Nova Scotia, and federal programs, expanding access for Canadians -
-
-
-
PRESS RELEASE
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
Bausch Health Canada Inc. launches CABTREO triple-combination gel for acne vulgaris, now accessible through public drug plans in Ontario, Nova Scotia, and federal government programs -
-
PRESS RELEASE
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Salix launches 'I Wish I Knew' campaign for Xifaxan, FDA-approved for hepatic encephalopathy. Advocating patient empowerment and education
